Table 4

Determinants of seropositivity among HPV-18 DNA positive women at enrollment; Demographic and sexual factors.

Women characteristics

Anti-HPV18

Unadjusted

Final model1


Negative

Positive

%

OR

(95% CI)

OR

(95% CI)


All women

76

103

57.5

Age

18-19

17

27

61.4

1.00

1.00

20-21

25

31

55.4

0.78

(0.35-1.74)

0.83

(0.36-1.91)

22-23

21

24

53.3

0.72

(0.31-1.67)

0.85

(0.30-2.40)

24-25

13

21

61.8

1.02

(0.41-2.55)

1.23

(0.39-3.85)

p trend

0.92

0.73

Age at sexual debut

≥ 18

24

21

46.7

1.00

1.00

17

13

26

66.7

2.29

(0.94-5.55)

2.29

(0.94-5.55)

16

12

21

63.6

2.00

(0.80-5.02)

2.00

(0.80-5.02)

15

17

14

45.2

0.94

(0.38-2.36)

0.94

(0.38-2.36)

< 15

10

21

67.7

2.40

(0.92-6.23)

2.40

(0.92-6.23)

p trend

0.36

0.36

Years since first sexual intercourse

≤ 1

9

11

55.0

1.00

1.00

2-3

18

30

62.5

1.36

(0.47-3.92)

1.25

(0.40-3.93)

4-5

18

23

56.1

1.05

(0.36-3.06)

0.87

(0.28-2.75)

≥ 6

31

39

55.7

1.03

(0.38-2.80)

0.77

(0.25-2.41)

p trend

0.70

0.32

Frequency sexual intercourse, month

≤ 1

17

21

55.3

1.00

1.00

2-3

18

7

28.0

0.31

(0.11-0.93)

0.25

(0.08-0.78)

4-9

24

35

59.3

1.18

(0.52-2.69)

0.97

(0.39-2.39)

≥ 10

16

39

70.9

1.97

(0.83-4.68)

1.47

(0.57-3.81)

p trend

0.03

0.13

Lifetime number of sexual partners

1

20

28

58.3

1.00

1.00

2

18

22

55.0

0.87

(0.37-2.04)

0.89

(0.37-2.15)

≥ 3

38

53

58.2

1.00

(0.49-2.02)

1.02

(0.48-2.17)

p trend

0.96

0.91

Time with most recent partner, months

< 4

18

24

57.1

1.00

1.00

4-13

26

34

56.7

0.98

(0.44-2.17)

0.81

(0.35-1.91)

> 13

32

45

58.4

1.05

(0.49-2.26)

0.84

(0.35-2.04)

p trend

0.87

0.74


NOTE. HPV, human papillomavirus; OR, odds ratio; CI, confidence interval.

1 For each variable considered the final model adjusts for all variables that changed the crude estimate of risk by 15% or more.

Age: was adjusted for years since first sexual intercourse.

Age at sexual debut: was not adjusted for any co-factors since none of the potential confounders evaluated changed the OR estimates by 15% or more.

Years since first sexual intercourse: was adjusted for use of hormonal contraceptives.

Frequency sexual intercourse, month: was adjusted for use of hormonal contraceptives.

Lifetime number of sexual partners: was adjusted for time with most recent partner.

Time with most recent partner: was adjusted for lifetime number of sexual partners and use of hormonal contraceptives.

Porras et al. BMC Infectious Diseases 2010 10:238   doi:10.1186/1471-2334-10-238

Open Data